Activity of tigecycline and comparators against recent clinical isolates of Finegoldia magna from Europe.
A total of 206 clinical isolates of Finegoldia magna were collected during the period 2007-2009 from six European countries. The majority of isolates were from body fluids (n = 83; 40.3%) or wounds (n = 82; 39.8%). All isolates were susceptible to tigecycline, meropenem, metronidazole and piperacillin / tazobactam, though susceptibility to penicillin (86.4-87.4%) and clindamycin (78.2-93.3%) were more variable.
Hawser
S P
SP
IHMA Europe Sàrl, 4 Route de la Corniche, Epalinges, Switzerland. shawser@ihmainc.com
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001826:Body Fluids / Q000382:microbiology; D005060:Europe; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D000078304:Tigecycline; D014947:Wounds and Injuries / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline